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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal fibrotic disorder, with no
curative therapies. The signal transducer and activator of transcription 3 (STAT3) protein is activated in lung fibroblasts
and alveolar type II cells (ATII), thereby contributing to lung fibrosis in IPF. Although activation of Janus kinase 2 (JAK2)
has been implicated in proliferative disorders, its role in IPF is unknown. The aim of this study was to analyze JAK2
activation in IPF, and to determine whether JAK2/STAT3 inhibition is a potential therapeutic strategy for this disease.
Methods and results: JAK2/p-JAK2 and STAT3/pSTAT3 expression was evaluated using quantitative real time-PCR,
western blotting, and immunohistochemistry. Compared to human healthy lung tissue (n = 10) both proteins were
upregulated in the lung tissue of IPF patients (n = 12). Stimulating primary ATII and lung fibroblasts with transforming
growth factor beta 1 or interleukin (IL)-6/IL-13 activated JAK2 and STAT3, inducing epithelial to mesenchymal and
fibroblast to myofibroblast transitions. Dual p-JAK2/p-STAT3 inhibition with JSI-124 or silencing of JAK2 and STAT3
genes suppressed ATII and the fibroblast to myofibroblast transition, with greater effects than the sum of those
obtained using JAK2 or STAT3 inhibitors individually. Dual rather than single inhibition was also more effective for
inhibiting fibroblast migration, preventing increases in fibroblast senescence and Bcl-2 expression, and ameliorating
impaired autophagy. In rats administered JSI-124, a dual inhibitor of p-JAK2/p-STAT3, at a dose of 1 mg/kg/day,
bleomycin-induced lung fibrosis was reduced and collagen deposition in the lung was inhibited, as were JAK2
and STAT3 activation and several markers of fibrosis, autophagy, senescence, and anti-apoptosis.
Conclusions: JAK2 and STAT3 are activated in IPF, and their dual inhibition may be an attractive strategy for
treating this disease.
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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive, and fatal form of fibrosing interstitial pneumonia of
unknown cause. The typical clinical course includes dys-
pnea, decreased exercise capacity, dry cough, and death at
2.5–5 years after diagnosis [1]. Although recent studies
have provided insights into the pathophysiology of IPF,
treatment options for this disease remain limited [1]. A pre-
requisite for the development of potential therapeutic
targets is a better understanding of the pathogenesis of IPF.
IPF is characterized by heterogeneous pulmonary lesions
at different stages of evolution, with foci of proliferative
fibroblasts and myofibroblasts, abnormal lung epithelial
cells, and an overwhelming matrix accumulation in the lung
interstitium [2]. The origins of the invasive lung myofibro-
blasts and their activation are unknown but are probably
multiple, including activation of lung resident fibroblasts,
recruitment of circulating fibrocyte blood mesenchymal
precursors, and mesenchymal transformations of alveolar
type II epithelial cells (ATII), endothelial cells, pericytes,
and mesothelial cells [3].
Transforming growth factor beta 1 (TGF-β1) is a well-
studied, profibrotic growth factor that plays a key role in
IPF by driving lung fibroblast activation and promoting
mesenchymal transformations of different cell types [2].
However, other important fibrogenic mediators are also
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elevated in diseased lung tissue and participate in the
pathogenesis of IPF [2, 3]. Therefore, an effective treat-
ment for IPF must address its multiple mechanisms.
Tyrosine kinases are a complex, heterogeneous group of
cell signal transducers that regulate a wide variety of
physiological cell processes including metabolism, growth,
differentiation, and apoptosis [4]. Deregulated tyrosine
kinase activity can promote the development and progres-
sion of neoplastic, cardiovascular, and fibrotic diseases.
Currently, the only two drugs approved for the treatment
of IPF are pirfenidone and nintedanib [1]. Nintedanib, a
multi-tyrosine kinase inhibitor, ameliorates IPF progres-
sion and symptoms by blocking the tyrosine kinases
coupled to platelet-derived growth factor (PDGF), fibro-
blast growth factor (FGF), and vascular endothelial growth
factor (VEGF) receptors [5, 6]. It is therefore likely that
specific tyrosine kinase inhibition can block the signal
transduction of multiple key mediators of fibrosis.
Janus kinases (JAKs) are receptor-associated tyrosine
kinases with central roles in cytokine and growth fac-
tor signaling. Like other receptor-associated tyrosine
kinases, cytokine binding induces autophosphorylation
and activation of JAK kinases [7]. In turn, JAK kinases
recruit and phosphorylate signal transducer and acti-
vator of transcription (STAT) proteins. Upon activa-
tion, STATs dimerize and translocate to the nucleus,
where they activate the transcription of several target
genes [7]. Alterations in JAK2 signaling cause pro-
found changes in the cellular response to cytokine
stimulation. TGF-β1 signaling induces phosphoryl-
ation and activation of JAK2, which then interacts and
phosphorylates STAT3 to induce fibrotic responses [8].
In addition, JAK2 can be activated by other profibrotic
mediators, including PDGF, VEGF, interleukin (IL)-6,
IL-13, angiotensin II (ANGII), serotonin (5-HT), and
endothelin (ET-1) [9, 10]. STAT3 phosphorylation has
been detected in fibrotic lung tissue from IPF patients
and participates in both the fibroblast to myofibroblast
transition and lung epithelial cell damage; therefore, it
is an attractive therapeutic target in IPF [11–13]. By
contrast, the role of JAK2 in IPF has not been studied.
Several JAK2 and STAT3 inhibitors are currently being
evaluated in clinical trials involving various malignan-
cies and inflammatory diseases. Thus, demonstration
of anti-fibrotic effects in experimental models of fibro-
sis may have direct translational implications. In this
study, we established different in vitro and in vivo
models relevant to IPF to analyze the participation of
JAK2 in IPF and the dependent and independent rela-
tionships of this protein with STAT3.
Methods
See the Online Supplement for more detailed descrip-
tions of these methods.
Patients
Human lung tissue was obtained from IPF patients who
underwent surgery for organ transplantation (n = 12).
Healthy lung explant control samples were obtained
from the organ transplant program of the University
General Consortium Hospital of Valencia, Spain. The
protocol was approved by the local research and inde-
pendent ethics committee of the University General
Consortium Hospital of Valencia (CEIC21/2013). In-
formed written consent was obtained from each patient.
Isolation and culture of human ATII cells and lung
fibroblasts and in vitro experimental conditions
Primary ATII cells were obtained from the lung paren-
chyma of IPF patients as previously outlined [14]. The
cells were suspended in Dulbecco’s Modified Eagle’s
Medium plus 10% fetal calf serum, 2 mM L-glutamine,
100 U penicillin/mL, and 100 g streptomycin/mL. Pri-
mary human lung fibroblasts were obtained from the
lung parenchyma of IPF patients with macroscopically fi-
brotic areas of disease, as previously described [15]. The
A549 human alveolar type II cell line and MRC5 normal
lung fibroblasts were purchased from the American
Type Culture Collection (Rockville, MD, USA) and cul-
tured in supplemented Roswell Park Memorial Institute
1640 medium as outlined [16]. For the in vitro studies,
ATII/A549 or primary lung fibroblast/MRC5 were stim-
ulated with recombinant TGF-β1 (5 ng/mL; Sigma Al-
drich, St. Louis, MO, USA) or IL-6 (50 ng/mL; Sigma)
together with IL-13 (50 ng/mL; Sigma) for the indicated
times, replacing the culture medium and stimulus every
24 h. TGF-β1 (5 ng/mL), IL-6 (50 ng/mL), and IL-13
(50 ng/mL) have been shown to induce cell phenotypic
changes, including epithelial to mesenchymal transition,
at the concentrations used in this study [14, 17, 18]. JSI-
124 (Sigma) is a selective JAK2/STAT3 inhibitor that at
a concentration of 1 μM suppresses JAK2/STAT3 activa-
tion in A549 cells [19]; NSC-33994 (Sigma) is a selective
JAK2 inhibitor that at 1 μM completely inhibits JAK2
activity without affecting other tyrosine kinases [20]); 5,
15-DPP (Sigma) is a selective STAT3 inhibitor that at
1 μM completely inhibits STAT3 activity without affect-
ing other STATs [21]. These inhibitors were added
30 min before the stimulus and left in the medium to-
gether with the stimulus until the effects were evaluated.
Trypan blue staining of the cells was > 95%, which
showed that none of the drugs altered viability.
Western blotting
Changes in the expression levels of proteins in human and
rat lung tissues, in ATII/A549, and in lung fibroblast/MRC5
were examined by western blotting. The bands shown on
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the films were analyzed by densitometry using Image J
1.42q software (available at http://rsb.info.nih.gov/ij/,
Bethesda, MD, USA). Target protein levels are
expressed as the percentage of the densitometry
values of the endogenous control (β-actin).
Small interfering RNA experiments
Total RNA was isolated from cells/lung tissue using
TriPure® isolation reagent (Roche, Indianapolis, IN,
USA) as previously described [22]. Small interfering
RNAs (siRNAs), including the scrambled siRNA control
and JAK2 and STAT3 gene-targeted siRNAs, were designed
by Ambion (Huntingdon, Cambridge, UK). A549 and
MRC5 cells were transfected with siRNA (50 nM) in serum
and antibiotic-free medium as previously reported [23].
Histological and immunohistochemical studies
Lung histology and immunohistochemistry were con-
ducted as previously reported [24]. Tissue blocks (4 μm
thickness) were stained with hematoxylin & eosin to as-
sess fibrotic injury and pulmonary artery remodeling,
and with Masson’s trichrome (Sigma-Aldrich, Madrid,
Spain) to detect collagen deposition. The severity of
lung fibrosis was scored on a scale from 0 (normal
lung) to 8 (total fibrotic obliteration of tissue in the
examined fields) according to Ashcroft [25]. For immu-
nohistochemical analysis of rat and human lung, the
tissues were fixed and embedded in paraffin, cut into
sections (4–6 μm), and incubated with JAK2, pJAK2,
STAT3, pSTAT3, collagen type I, LC3II, beclin-I, Bcl-2,
and p21 antibodies for 24 h at 4 °C. The non-immune
IgG isotype control was used as the negative control for
all of the samples.
ELISA
IL-6 and IL-13 cytokines were analyzed in the cell cul-
ture supernatants of human ATII and fibroblast using
commercially available Quantikine® ELISA kits for hu-
man IL-6 (Catalog No. D6050; R&D Systems, Madrid,
Spain) and IL-13 (Catalog No. D1300B), and in the
bronchoalveolar lavage (BAL) fluid of rats using the ELISA
rat IL-6 (Catalog No. KRC0061; Invitrogen™, Madrid,
Spain) and IL-13 (Catalog No. KRC0132; Invitrogen™) kits
according to the manufacturers’ protocols.
Wound repair and cell proliferation assay
Wound repair studies were performed in IPF primary
human lung fibroblasts as previously outlined [26]. The
proliferation of IPF primary human lung fibroblasts was
measured in a colorimetric immunoassay based on BrdU
incorporation during DNA synthesis, which was per-
formed using a cell proliferation ELISA BrdU kit (Roche,
Mannheim, Germany) as previously described [27].
Micro-computed tomography imaging of intratracheal
bleomycin animals and BAL
Animal experiments and handling were performed in
accordance with the guidelines of the Committee of
Animal Ethics and Well-being of the University of
Valencia (Valencia, Spain) as previously outlined [24].
After the rats had been anesthetized with ketamine/
medetomidine, a single dose of bleomycin at 3.75 U/
kg (dissolved in 200 μL saline) was administered intra-
tracheally via the endotracheal route [28]. Sham-treated
rats received the identical volume of intratracheal saline
instead of bleomycin. This procedure defined day 1 of the
experiment. The dose of intraperitoneally administered
JSI-124 (1 mg/kg/day) was selected based on the results
of previous in vivo animal studies [29]. The inhibitor
was administered from day 14 to day 28 as a therapeutic
protocol. BAL fluid was processed as previously outlined,
and the contents of inflammatory cells, protein, and IL-6/
IL-13 were measured [30]. Micro-computed tomography
(micro-CT) analyses were performed as previously re-
ported [31]. Densitometric analysis of the extension of
fibrosis was performed using the micro-CT images,
with the density expressed as Hounsfield units.
Statistical analysis
The results were statistically analyzed using non-parametric
tests (human tissue studies) and expressed as medians and
interquartile ranges. In comparisons of two groups,
between-group differences were analyzed using the Mann–
Whitney test. Parametric tests were used to analyze the
data obtained in animal and cellular in vitro mechanistic
experiments; the results are expressed as the mean ± SEM
of n experiments. Two-group comparisons were analyzed
using a two-tailed Student’s paired t-test for dependent
samples, and an unpaired t-test for independent samples.
Multiple comparisons were made using a one-way or two-
way analysis of variance followed by a Bonferroni post-hoc
test. A P value < 0.05 was considered statistically significant.
Results
JAK2 and STAT3 are increased and activated in the lungs
of IPF patients
Both control and IPF patients were prospectively recruited
from the Thoracic Surgery and Pathology Services of the
University General Consortium Hospital and University
and Polytechnic Hospital La Fe (Valencia, Spain) between
2013 and 2016 at the initial diagnostic work-up. The clin-
ical data of the patients are shown in Table 1. In homoge-
nized lung tissue, JAK2 and STAT3 mRNA transcript
levels were both higher in that of IPF patients than in that
of controls (p < 0.001 and p = 0.0035, respectively) (Fig. 1a),
as were JAK2 and STAT3 protein expression. In addition,
whereas the active phosphorylated forms of JAK2 and
STAT3 were upregulated in IPF lung tissue, the levels
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were almost undetectable in control lung tissue (Fig. 1b).
Immunohistochemistry of control lung sections showed
weak JAK2 and STAT3 expression that was localized
mainly to bronchial epithelium and alveolar macrophages
(Fig. 1c). By contrast, in IPF lung tissue, expression of
both markers was elevated in hyperplastic alveolar cells
(Fig. 1c, red arrows) and fibroblasts (Fig. 1c, black arrows).
The localization of phosphorylated JAK2 and STAT3 in
the nuclei of cells in fibrotic areas of the lung implies that
these proteins function as transcription factors.
Phosphorylation of JAK2 and STAT3 induces
mesenchymal transition in ATII and transition of
fibroblasts to myofibroblasts in the lung
In IPF tissue, TGF-β1 significantly increased IL-6 and
IL-13 release from ATII inhibited by JSI-124 (Fig. 2a),
but after 40 min of stimulation, neither JAK2 nor STAT3
was phosphorylated. However, after 24 h stimulation
(Fig. 2b), TGF-β1 enhanced p-JAK2 and p-STAT3 levels.
It also promoted ATII to mesenchymal transition, in-
creasing the mesenchymal markers αSMA and colla-
gen type I and downregulating the epithelial marker
E-cadherin (Fig. 2c). These changes were attenuated
by specific p-STAT3 and p-JAK2 inhibitors 5,15 DPP
and NSC33994, and suppressed by the dual p-JAK2/p-
STAT3 inhibitor JSI-124 (Fig. 2c). Stimulation of ATII
cells with a combination of IL-6/IL-13 increased p-
JAK2 and p-STAT3 expression (Fig. 2d). The phos-
phorylation of both proteins was inhibited by JSI-124
and NSC33994. However, the p-STAT3 inhibitor 5, 15
DPP inhibited only STAT3, not JAK2 phosphorylation
(Fig. 2d). The IL-6/IL-13 combination also increased
expression of mesenchymal markers in ATII cells, in-
cluding collagen type I protein and mRNA as well as
αSMA, Snail, and Slug mRNA, and decreased expres-
sion of the epithelial marker E-cadherin (Fig. 2d and
Additional file 1: Figure S1). The dual p-JAK2/p-
STAT3 inhibitor JSI-124 suppressed ATII to mesen-
chymal transition whereas the inhibitory effects of
NSC33994 and 5, 15 DPP were weaker (Fig. 2d). Similar





Age (yr) 57 [38–65] 66 [58–75]
Sex (M/F) 6/4 9/3
Smoking
Never smoked/Smokers 3/7 1/11
Pack-year 25 [0–28] 26.3 [11–34]
FEV1, pred ND 72.2 [56–96]
FVC, % pred ND 62.2 [55–68]
TLC, % pred ND 73.5 [45–89]
DLco, % pred ND 42.1 [31–51]
Ground glass % 0 25 [20–39]
Honeycombing % 0 35 [25–40]
NAC (y/n) 0/10 8/4
Pirfenidone (y/n) 0/10 4/8
% pred % predicted, DLco diffusion capacity of the lung for carbon monoxide,
FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, ND not determined,
Pack-year 1 year of smoking 20 cigarettes per day, TLC total lung capacity, Ground
glass % % of pulmonary parenchyma with ground glass on a computed
tomography (CT) image, Honeycombing % % of pulmonary parenchyma
with honeycombing on a CT image; N-acetyl-l-cysteine (NAC). Data are
medians [interquartile range]
Fig. 1 Expression and localization of JAK2, STAT3, and their phosphorylated forms in lung tissue from patients with IPF. JAK2 and STAT3
gene expression and JAK2/p-JAK2 and STAT3/p-STAT3 protein expression were analyzed in lung tissue from healthy controls (n = 10) and
IPF patients (n = 12) by (a) qPCR, (b) western blotting, and (c) immunohistochemistry. Scale bar: 100 μm. Black arrows indicate hyperplastic alveolar
type II cells, and red arrows indicate fibroblasts. Expression was calculated as the ratio compared to β-actin expression. The data are presented
as a scatter dot plot showing the median and interquartile range. Exact values for P were obtained using the Mann–Whitney test
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Fig. 2 Effects of JAK2 and STAT3 on ATII to mesenchymal and fibroblast to myofibroblast transitions. Primary ATII and lung fibroblasts were isolated
from the lungs of IPF patients. a The cells were incubated with the dual p-JAK2/p-STAT3 inhibitor JSI-124 for 30 min followed by TGF-β1 stimulation
for an additional 24 h. IL-6 and IL-13 levels in cell supernatants were measured using ELISA. b Ratios of JAK2/p-JAK2 and STAT3/p-STAT3 were
determined by western blotting in ATII cells stimulated for 40 min or 24 h with TGF-β1 in the presence or absence of JSI-124. c, d ATII cells
were pre-incubated for 30 min with 1 μM of the p-STAT3 inhibitor 5,15 DPP, the p-JAK2 inhibitor NSC33994, or the dual p-JAK2/p-STAT3 inhibitor JSI-124,
and then stimulated for 72 h with TGF-β1 (c) or IL-6/IL-13 (d). e Levels of IL-6 and IL-13 in primary fibroblasts. f JAK2/p-JAK2 and STAT3/p-STAT3 protein
expression in human lung fibroblasts. g, h Primary lung fibroblasts pre-incubated for 30 min with 1 μM of the p-STAT3 inhibitor 5,15 DPP, the
p-JAK2 inhibitor NSC33994, or the dual p-JAK2/p-STAT3 inhibitor JSI-124 and stimulated for 72 h with TGF-β1 (g) or IL-6/IL-13 (h). Representative western
blots are shown. The results are expressed as the mean (SEM) of n= 4 (cells from four IPF patients) experiments per condition. Two-way ANOVA followed
by post-hoc Bonferroni tests. *P< 0.05 vs. the solvent controls; #P< 0.05 vs. TGF-β1 or IL-6/IL-13; ┴ P< 0.05 vs. 5,15 DPP or NSC33994
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results were obtained in primary lung fibroblasts from IPF
patients. TGF-β1 significantly increased IL-6 and IL-13 re-
lease from lung fibroblasts, and after 24 h stimulation phos-
phorylated JAK2 and STAT3 (Fig. 2e and f). JSI-124
inhibited TGF-β1-induced IL-6 and IL-13 release from lung
fibroblasts as well as JAK2/STAT3 phosphorylation. TGF-
β1 promoted fibroblast to myofibroblast transition, which
was partially inhibited by NSC33994 and 5, 15 DPP and
completely suppressed by JSI-124 (Fig. 2g). Combin-
ation of IL-6 and IL-13 promoted fibroblast to myofi-
broblast transition, increasing expression of collagen
type I, αSMA, Snail, and Slug. The latter effect was sup-
pressed by JSI-124, and to a lesser extent by NSC33994
and 5, 15 DPP (Fig. 2h and Additional file 1: Figure S1).
In the A549 alveolar type II cell line, TGF-β1 increased
collagen type I and reduced E-cadherin protein expres-
sion, with both responses partially inhibited in cells se-
lectively transfected with siRNA-JAK2 or siRNA-STAT3,
and completely suppressed by dual siRNA-JAK2/STAT3
transfection (Fig. 3a and b). Similar results were ob-
tained using TGF-β1 or IL-6/IL-13 as an enhancer of
epithelial to mesenchymal transition, as both increased
collagen type I and E-cadherin gene mRNA expression
(Fig. 3c). TGF-β1 promoted increases in the senescence
of p21 fibroblasts and expression of Bcl-2 anti-apoptotic
markers but also decreases in LC3I/II autophagy markers
in A549 alveolar type II cells. These responses were par-
tially inhibited by incubation of the cells with siRNA-
JAK2 or siRNA-STAT3, and completely suppressed by
dual si-RNA-JAK2/STAT3 transfection (Fig. 3a and b).
Both TGF-β1 and IL-6/IL-13 increased collagen type I
gene expression in MRC5 cells, whereas siRNA-JAK2 and
siRNA-STAT3 partially inhibited this response and dual
siRNA-JAK2/STAT3 transfection completely inhibited this
response (Fig. 3c). IPF fibroblasts stimulated with IL-6/IL-
13 accelerated wound repair in vitro, indicative of the in-
creased migration capacity of these cells. JAK2 inhibition,
and to a lesser extent STAT3 inhibition, reduced fibroblast
migration, which was almost completely suppressed to
control levels after inhibition of JAK2/STAT3 by JSI-124
(Fig. 4a and b). JSI-124 was more effective than single in-
hibitors of JAK2 or STAT3 in blocking cell proliferation in
cultures containing fetal bovine serum (Fig. 4c). IL6/IL13
showed only weak effects on fibroblast proliferation sup-
pressed by JAK2 and STAT3 inhibitors (Fig. 4d).
Effects of JAK2/STAT3 dual inhibition on
bleomycin-induced lung fibrosis
Phosphorylation of JAK2 and STAT3 in rat lung tissue
increased after 28 days of intratracheal bleomycin instilla-
tion compared to control animals (Fig. 5). Phosphorylated
forms of JAK2 and STAT3 were not detected in con-
trol animals, but were increased in the lung tissue of
bleomycin-treated rats and located in the nuclei of fibrotic
cells. In control animals, non-phosphorylated JAK2 and
STAT3 were localized in bronchial epithelial cells,
whereas their expression was enhanced in the fibrotic
cells of bleomycin-treated rats. Daily intraperitoneal ad-
ministration of JSI-124 (1 mg/kg) from day 14 to 28 re-
duced JAK2 and STAT3 phosphorylation (Fig. 5) as
well as the increased protein levels and cell numbers in
BAL, lung mass and protein, and expression of IL-6
and IL-13 secondary to lung fibrosis (Fig. 6a–g). Bleomycin
induced a fibrotic response in the lung that was character-
ized by increased deposition of collagen, as seen on
Masson’s trichrome-stained sections, and a dense fibrotic
content, evident on micro-CT images (Fig. 6h–k).
Expression of several markers of fibrosis, including
collagen type I, connecting tissue growth factor (CTGF),
ET-1, TGF-β1, and p-SMAD3, was also increased in
bleomycin-treated rats and reduced by JSI-124 treatment
(Fig. 7). The latter alleviated the histologically observed,
multifocal fibrotic lesions, resulting in smaller, less-
organized foci, less septal enlargement, and accord-
ingly a diminished Ashcroft fibrosis score (Fig. 6i). Levels
of the autophagy marker LC3I/II and of beclin-1 de-
creased, and senescence p21 and anti-apoptotic Bcl-2
increased in the lungs of bleomycin-treated rats
(Additional file 1: Figure S2). JSI-124 increased au-
tophagy while decreasing the levels of p21 senescence and
Bcl-2 anti-apoptotic markers (Additional file 1: Figure S2).
Discussion
This study examined the role of JAK2 and STAT3 in
IPF. Increased STAT3 phosphorylation, which modulates
ATII and lung fibroblast plasticity [11, 12], is character-
istically detected in lung biopsy tissue from IPF patients,
but there is no evidence implying the involvement of
JAK2 in IPF. Our results show overexpression of JAK2
and its phosphorylated form in the fibrotic lungs of IPF
patients, thus paralleling previous STAT3 findings. JAK2
and STAT3 activation contributed to cell transforma-
tions typical of IPF, including the ATII to mesenchymal
and fibroblast to myofibroblast transitions and fibroblast
proliferation and migration. Dual JAK2/STAT3 inhib-
ition was more effective for inhibiting both these cellular
transitions and lung fibrosis than the individual inhib-
ition of JAK2 or STAT3, which implies synergistic and
independent roles of these proteins in IPF.
In this study, non-phosphorylated forms of STAT3
were overexpressed in lung tissue from IPF patients and
localized in the cytoplasm of fibroblasts from fibrotic
areas and in hyperplastic ATII cells, as previously re-
ported [12]. The nuclear localization of p-STAT3 in
fibrotic areas of lungs from IPF patients is consistent
with its role as a transcription factor modulating the
expression of the genes that cause fibrosis [11]. Similar
to STAT3, non-phosphorylated JAK2 was overexpressed
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in the fibrotic lungs of IPF patients and localized both in
fibroblasts from fibrotic areas and in ATII hyperplastic
cells, which implies a dominant role for these cells in
IPF. Surprisingly, the active phosphorylated form of
JAK2 was not detected in control healthy lungs, but was
also overexpressed and localized in the nuclei of cells
from the fibrotic areas of the lungs of IPF patients and
bleomycin-treated animals. These are novel observa-
tions, as JAK2 and its phosphorylated form are typically
located in the cytoplasm. JAK2 is phosphorylated in re-
sponse to cell stimulation by different cytokines or
growth factors, including TGF-β1, which leads to the
translocation of STAT3 to the nucleus, where it activates
genes associated with fibrosis [8]. The similar nuclear
localization of p-JAK2 in fibrotic areas implies that it is
a non-canonical transcription factor, with a pathway in-
dependent of the canonical STAT3 pathway. Previous re-
ports of the nuclear localization of p-JAK2 support our
findings [32, 33], while emerging evidence indicates that
nuclear pJAK2 plays important roles in physiological
and pathological conditions characterized by heightened
cellular growth. Therefore, p-JAK2 activates not only
STAT3 but also different intracellular receptors and
forms multiprotein complexes [33]. However the exact
role of nuclear p-JAK2 in IPF is beyond the scope of the
present work. Consistent with an independent role of p-
JAK2 in lung fibrosis, we observed that p-JAK2 inhib-
ition in ATII and lung fibroblasts from IPF patients
partially reduced the mesenchymal-myofibroblast trans-
formation induced by TGF-β1 and IL-6/IL-13. The de-
gree of inhibition was similar to that of p-STAT3
inhibition. Moreover, the inhibition of p-JAK2/STAT3,
whether by JSI-124 or by gene silencing, was synergistic
in its inhibitory effects on cell transformation.
Overexpression of p-JAK2 has also been reported in
the cytoplasm of skin fibroblasts from systemic sclerosis
(SSc) patients [8]. In SSc, TGF-β1 independently acti-
vates JAK2 and STAT3 via SMAD3, and pharmacologic
Fig. 3 Dual JAK2/STAT3 gene silencing suppressed ATII to mesenchymal and fibroblast to myofibroblast transitions. ATII A549 and human
lung fibroblast MRC5 cell lines were transfected with control siRNA(−), siRNA-JAK2, siRNA-STAT3, or both siRNA-JAK2/STAT3 and stimulated
for 72 h with TG-Fβ1 or IL-6/IL-13 at a concentration of 5 ng/mL. a Total protein and RNA from cell lysates were analyzed by (a, b) western
blot and (c) qPCR. Mesenchymal collagen type I and epithelial E-cadherin markers were measured using (a) western blot and (c) qPCR. Senescence
p21, autophagy LC3I/II, and anti-apoptotic BCL-2 markers were (a) measured using western blot and (b) quantified by densitometry. Data are expressed
as the ratio to β-actin protein and mRNA levels. The results are expressed as the mean (SEM) of n = 4 independent experiments per condition.
One-way ANOVA followed by post-hoc Bonferroni tests. *P < 0.05 vs. the solvent controls; #P < 0.05 vs. TGF-β1 or IL-6/IL-13; ┴ P < 0.05 vs. siRNA-JAK2
or siRNA-STAT3
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Fig. 4 Fibroblast migration and proliferation in IPF were dependent on JAK2 and STAT3 activation. a, b Primary human fibroblasts from IPF
patients were pre-treated for 30 min with 1 μM of the p-STAT3 inhibitor 5,15 DPP, the p-JAK2 inhibitor NSC33994, or the dual p-JAK2/p-STAT3 inhibitor
JSI-124 and then cell migration was assessed. A scrape-wound was created by using a sterile p200 pipette tip to make a perpendicular linear scratch in
the culture. After the cells had been washed, culture medium with or without pharmacologic modulators and IL-6/IL-13 was added. The size of
the wound remaining was analyzed at the indicated times and expressed as a percentage of the initial wound area. c Fibroblast proliferation
during 48 h was evaluated by the BrdU assay. Different JAK2 and STAT3 inhibitors were added 30 min before 10% fetal bovine serum (FBS) or
(c) 50 ng IL-6/IL-13/mL (d) was added as the stimulus. Values are expressed as relative absorbance (450 nm) units. The results are expressed as
the mean (SEM) of n= 4 (cells from four IPF patients) experiments per condition. Two-way ANOVA followed by post-hoc Bonferroni tests. *P< 0.05 vs. the
solvent controls; #P< 0.05 vs. IL-6/IL-13 or 10% FBS; ┴ P< 0.05 vs. 5,15 DPP or NSC33994
Fig. 5 Bleomycin induced lung fibrosis and JAK2 and STAT3 activation. Wistar rats were administered a single intratracheal dose of bleomycin
(BLM; 3.75 U/kg) on day 1. JSI-124 (1 mg/kg/day) or vehicle was administered intraperitoneally from day 14 until the analysis at day 28 (n = 10
per group). Lung tissue from the vehicle control, BLM, and BLM+ JSI-124 groups was immunostained for JAK2, p-JAK2, STAT3, and p-STAT3 (brown) and
counterstained with hematoxylin. Representative (a) immunohistochemistry and (b) western blot images are shown. Scale bar = 100 μm. The IgG isotype
control was negative (data not shown). Data are expressed as the ratio to β-actin for protein levels. The results are expressed as the mean (SEM), n = 10.
One-way ANOVA followed by post-hoc Bonferroni tests. *P < 0.05 vs. controls; #P < 0.05 vs. BLM
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or genetic inactivation of JAK2 in skin reduces the profi-
brotic effects of TGF-β1 [8]. However, recent evidence
indicates that in fibroblasts from IPF patients, TGF-β1
activates STAT3 via a SMAD2/3-dependent mechanism,
independent of JAK2 [12]. A physical interaction be-
tween STAT3 and the TGF-β receptor I and between
STAT3 and SMAD3 in different cell lines has been sug-
gested [34]. Alternatively, TGF-β1 may activate STAT3
Fig. 6 JSI-124 inhibited bleomycin-induced bronchoalveolar inflammatory cell extravasation and lung fibrosis. Wistar rats were administered a single
intratracheal dose of bleomycin (BLM; 3.75 U/kg) on day 1. JSI-124 (1 mg/kg/day) or vehicle was administered intraperitoneally from day 14
until the analysis at day 28 (n = 10 per group). Total bronchoalveolar lavage (a) protein, (b, c) inflammatory cells, (d) lung weight, (e) protein,
and (f, g) IL-6 and IL-13 content were measured at day 28. h Masson’s trichrome (upper panels, scale bar: 100 μm) of control, BLM,
and BLM + JSI-124 tissue. i Fibrosis Ashcroft scores were assessed as described in the Methods. j Micro-CT images were acquired on
day 28 and (k) quantified as Hounsfield units. The results are expressed as the mean ± SEM, n = 10. Statistical significance was assessed
using a t-test or one-way ANOVA followed by a Bonferroni post-hoc test. *P < 0.05 vs. control, #P < 0.05 vs. BLM
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indirectly by inducing IL-6, IL-13, or other activators [35].
In this study, TGF-β1 was shown to increase IL-6 and IL-
13 secretion in IPF ATII and fibroblasts after 24 h, to
phosphorylate JAK2 and STAT3, which implies either
slow or indirect activation of these proteins. In addition to
TGF-β1, other important fibrogenic mediators with in-
creased expression in IPF lung tissue were CTGF, PDGF,
FGF-2, ET-1, ANGII, and cytokines such as IL-13, IL-6,
and chemokine ligand 2, all of which have been implicated
in the pathogenesis of this disease [2, 3]. Of note, most
mediators activate JAK2 or STAT3 [9, 10]. In this study,
bleomycin-induced pulmonary fibrosis was characterized
by increases in CTGF, TGFβ1, ET-1, IL-6, and IL-13, as
profibrotic mediators. Thus, inhibition of downstream
JAK2 and STAT3 signaling by JSI-124 reduced both pul-
monary fibrosis and expression of these mediators in the
lung. Accordingly, inhibition of JAK2 and STAT3, and
thus of several of the cellular pathways implicated in IPF,
may be a strategy for treating this complex disease.
Senescence and impaired autophagy are hallmarks of fi-
broblasts isolated from IPF patients. Autophagy, which
helps to maintain the balanced synthesis, degradation, and
recycling of organelles and proteins to meet metabolic de-
mands, plays an important regulatory role in cellular sen-
escence and differentiation. Impaired autophagy and
increased senescence promote myofibroblast formation in
IPF and thus are attractive targets in its treatment. In this
work, TGFβ1 increased p21 senescence and Bcl-1 anti-
apoptotic markers while decreasing the autophagy marker
LC3-I/II in human fibroblasts. Similar results were ob-
served in fibrotic lung tissue from bleomycin-treated rats.
As in their cellular transformations, JAK2 and STAT3 ex-
hibited independent effects on autophagy and senescence,
with dual JAK2 and STAT3 inhibition leading to greater
reductions in cell senescence and higher levels of autoph-
agy than achieved by inhibiting either protein alone. Previ-
ous reports have demonstrated a role for STAT3 in
fibroblast senescence [36], consistent with the relevance of
the JAK2/STAT3 pathway in IPF. However, the individual
mechanisms by which JAK2 and STAT3 cause pulmonary
fibrosis are currently unknown, and together with the
mechanism underlying the synergistic effects of dual in-
hibition, remain to be determined in future research.
Conclusion
Levels of activated JAK2 and STAT3 are elevated in lung
fibroblasts and ATII cells from IPF patients. These two
proteins participate in lung fibrosis by dependent and in-
dependent mechanisms that may be targetable in the
treatment of IPF. Because JAK2 and STAT3 inhibitors
are currently being evaluated in clinical trials for malig-
nancies and inflammatory diseases, the results provided
in this study may have direct translational implications.
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Fig. 7 JSI-124 inhibited the bleomycin-induced expression of molecular markers of lung fibrosis. Wistar rats were administered a single intratracheal
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